A significant increase of 3 days. It has been announced to the Japanese Patent Office that a patent application relating to a conjugate (complex formation by chemical bonding) between aptamer and polyethyloxazoline and extending its half-life in blood has been completed. It was discovered that the conjugate of aptamer and polyethyloxazoline shows excellent internal dynamics and is an alternative compound for polyethylene glycol (PEG). Quality control of compounds is easy, and it is expected that they will be supplied at low cost in the future.
リボミック---大幅に3日続伸、新規PEG代替技術を開発、特許出願完了
Ribomic---Continued significant growth for 3 days, developed a new PEG replacement technology, and completed a patent application
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.